Natera Inc (Natera) develops genetic and cell-free deoxyribonucleic acid (cfDNA) testing solutions. The company’s products include Signatera, a personalized ctDNA (circulating tumor DNA) blood test to assess MRD (molecular residual disease) and its recurrence; Aletra, a tissue-based genomic profiling test to identify genomic alterations and oncology biomarkers in a tumor; Prospera, a transplant rejection test to evaluate the risk of rejection of a transplanted kidney. It also offers a Renasight test to detect the genetic causes of kidney diseases, Horizon carrier screening test, Panorama non-invasive prenatal screening test, Empower hereditary cancer test, Vistara prenatal single gene screening test, Anora miscarriage test and Spectrum preimplantation genetic test. Natera is headquartered in Austin, Texas, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Natera Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Natera Inc Company Overview
- Natera Inc Company Snapshot
- Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
- Natera Inc - Pipeline Analysis Overview
- Natera Inc - Key Facts
- Natera Inc - Major Products and Services
- Natera Inc Pipeline Products by Development Stage
- Natera Inc Ongoing Clinical Trials by Trial Status
- Natera Inc Pipeline Products Overview
- Expanded NIPS Test
- Expanded NIPS Test Product Overview
- Panorama Non-Invasive Prenatal Expanded Test
- Panorama Non-Invasive Prenatal Expanded Test Product Overview
- Prospera Pancreas Transplant Rejection Test
- Prospera Pancreas Transplant Rejection Test Product Overview
- Reproductive Health Test
- Reproductive Health Test Product Overview
- Signatera - Breast Cancer
- Signatera - Breast Cancer Product Overview
- Signatera - Breast Cancer Clinical Trial
- Signatera - Colorectal Cancer
- Signatera - Colorectal Cancer Product Overview
- Signatera - Colorectal Cancer Clinical Trial
- Signatera - GI Tumors
- Signatera - GI Tumors Product Overview
- Signatera - GI Tumors Clinical Trial
- Signatera - Lung Cancer (Opdivo)
- Signatera - Lung Cancer (Opdivo) Product Overview
- Signatera - Lung Cancer (Opdivo) Clinical Trial
- Signatera - Metastatic Non-Small Cell Lung Cancer
- Signatera - Metastatic Non-Small Cell Lung Cancer Product Overview
- Signatera - Multiple Myeloma
- Signatera - Multiple Myeloma Product Overview
- Signatera - Non-Hodgkin's Lymphoma
- Signatera - Non-Hodgkin's Lymphoma Product Overview
- Signatera - Ovarian Cancer
- Signatera - Ovarian Cancer Product Overview
- Signatera - Ovarian Cancer Clinical Trial
- Signatera - Pan-Cancer
- Signatera - Pan-Cancer Product Overview
- Signatera - Pancreatic Cancer
- Signatera - Pancreatic Cancer Product Overview
- Signatera - Prostate Cancer
- Signatera - Prostate Cancer Product Overview
- Signatera Companion Diagnostic - Tecentriq
- Signatera Companion Diagnostic - Tecentriq Product Overview
- Signatera MRD Test
- Signatera MRD Test Product Overview
- Signatera MRD Test Clinical Trial
- Natera Inc - Key Competitors
- Natera Inc - Key Employees
- Natera Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Natera Inc, Recent Developments
- Jun 04, 2025: Natera Announces Medicare Coverage for Signatera Genome
- Jun 02, 2025: Signatera Genome Clinical Performance Highlighted at ASCO 2025
- May 22, 2025: Natera to Present over 25 Signatera Studies at 2025 ASCO Annual Meeting
- May 08, 2025: Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
- May 07, 2025: Prospera Heart Test With DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
- May 06, 2025: Natera reports outcomes from study of MRD test for soft tissue and bone sarcomas
- Apr 29, 2025: Prospective DEFINE-HT Study Demonstrates that Prospera Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
- Apr 22, 2025: Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
- Mar 25, 2025: DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
- Mar 10, 2025: Natera Announces Enrollment of First Patients in the Heroes Clinical Trial in Metastatic HER2+ Breast Cancer
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Natera Inc Pipeline Products and Ongoing Clinical Trials Overview
- Natera Inc Pipeline Products by Equipment Type
- Natera Inc Pipeline Products by Indication
- Natera Inc Ongoing Clinical Trials by Trial Status
- Natera Inc, Key Facts
- Natera Inc, Major Products and Services
- Natera Inc Number of Pipeline Products by Development Stage
- Natera Inc Pipeline Products Summary by Development Stage
- Natera Inc Ongoing Clinical Trials by Trial Status
- Natera Inc Ongoing Clinical Trials Summary
- Expanded NIPS Test - Product Status
- Expanded NIPS Test - Product Description
- Panorama Non-Invasive Prenatal Expanded Test - Product Status
- Panorama Non-Invasive Prenatal Expanded Test - Product Description
- Prospera Pancreas Transplant Rejection Test - Product Status
- Prospera Pancreas Transplant Rejection Test - Product Description
- Reproductive Health Test - Product Status
- Reproductive Health Test - Product Description
- Signatera - Breast Cancer - Product Status
- Signatera - Breast Cancer - Product Description
- Signatera - Breast Cancer - A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- Signatera - Breast Cancer - De-escalation of Medical Therapies in HER2-positive Metastatic Breast Cancer in Long-term Persistent Response and Minimal Residual Disease Undetectable in Circulating Tumor DNA
- Signatera - Breast Cancer - Elacestrant for Treating ER+/HER2- Breast Cancer Patients with ctDNA Relapse
- Signatera - Breast Cancer - Personalized Detection of CtDNA for Patients with HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
- Signatera - Breast Cancer - Pre-operative Phase II Trial for Breast Cancer with Nivolumab in Combination with Novel IO (BELLINI Trial)
- Signatera - Breast Cancer - Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
- Signatera - Colorectal Cancer - Product Status
- Signatera - Colorectal Cancer - Product Description
- Signatera - Colorectal Cancer - BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Signatera - Colorectal Cancer - Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II
- Signatera - Colorectal Cancer - Clinical Experience of a Personalized and Tumor-informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients
- Signatera - Colorectal Cancer - Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Signatera - Colorectal Cancer - Genetic Alterations and Clinical Record in Radically Resected Colorectal Cancer Revealed by Liquid Biopsy and Whole Exome Analysis
- Signatera - Colorectal Cancer - Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
- Signatera - GI Tumors - Product Status
- Signatera - GI Tumors - Product Description
- Signatera - GI Tumors - Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) - a Phase Ib Feasibility Trial
- Signatera - Lung Cancer (Opdivo) - Product Status
- Signatera - Lung Cancer (Opdivo) - Product Description
- Signatera - Lung Cancer (Opdivo) - Neoadjuvant Anti-PD-1 Drug Nivolumab Combined with Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma
- Signatera - Metastatic Non-Small Cell Lung Cancer - Product Status
- Signatera - Metastatic Non-Small Cell Lung Cancer - Product Description
- Signatera - Multiple Myeloma - Product Status
- Signatera - Multiple Myeloma - Product Description
- Signatera - Non-Hodgkin's Lymphoma - Product Status
- Signatera - Non-Hodgkin's Lymphoma - Product Description
- Signatera - Ovarian Cancer - Product Status
- Signatera - Ovarian Cancer - Product Description
- Signatera - Ovarian Cancer - Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation
- Signatera - Pan-Cancer - Product Status
- Signatera - Pan-Cancer - Product Description
- Signatera - Pancreatic Cancer - Product Status
- Signatera - Pancreatic Cancer - Product Description
- Signatera - Prostate Cancer - Product Status
- Signatera - Prostate Cancer - Product Description
- Signatera Companion Diagnostic - Tecentriq - Product Status
- Signatera Companion Diagnostic - Tecentriq - Product Description
- Signatera MRD Test - Product Status
- Signatera MRD Test - Product Description
- Signatera MRD Test - A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients with High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
- Signatera MRD Test - MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
- Natera Inc, Key Employees
- Natera Inc, Other Locations
- Natera Inc, Subsidiaries
- Glossary
- Natera Inc Pipeline Products by Equipment Type
- Natera Inc Pipeline Products by Development Stage
- Natera Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adaptive Biotechnologies Corp
- Roche Diagnostics International Ltd
- Exact Sciences Corp
- Guardant Health Inc
- Personal Genome Diagnostics Inc
